Marinus Pharmaceuticals (MRNS)
(Delayed Data from NSDQ)
$9.04 USD
+0.19 (2.15%)
Updated Mar 28, 2024 04:00 PM ET
After-Market: $9.02 -0.02 (-0.22%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth C Momentum F VGM
Price, Consensus and EPS Surprise
MRNS 9.04 +0.19(2.15%)
Will MRNS be a Portfolio Killer in March?
Zacks Investment Research is releasing its prediction for MRNS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for MRNS
Do Options Traders Know Something About Marinus (MRNS) Stock We Don't?
Marinus Pharmaceuticals (MRNS) Reports Q4 Loss, Lags Revenue Estimates
MRNS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Amneal Pharmaceuticals (AMRX) Beats Q4 Earnings Estimates
Strength Seen in Catalent (CTLT): Can Its 9.7% Jump Turn into More Strength?
Should You Add Marinus (MRNS) Stock to Your Portfolio Now?
Other News for MRNS
Analysts Conflicted on These Healthcare Names: Cellectar Biosciences (CLRB), MiMedx Group (MDXG) and Marinus (MRNS)
Marinus Pharmaceuticals Comments on Patent Challenge by Ovid Therapeutics Inc. and Provides Update on Marinus’ Post Grant Review
Marinus Comments on patent challenge by Ovid Therapeutics
Analysts Offer Insights on Healthcare Companies: Marinus (MRNS), Arcutis Biotherapeutics (ARQT) and Axsome Therapeutics (AXSM)
Peeling Back The Layers: Exploring Marinus Pharma Through Analyst Insights